...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell cycle >Analysis of FDA approved anticancer drugs reveals the future of cancer therapy.
【24h】

Analysis of FDA approved anticancer drugs reveals the future of cancer therapy.

机译：FDA批准的抗癌药物分析揭示了癌症治疗的未来。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This review discusses 26 new anticancer drugs approved by the FDA in the past decade. Based on their targets, these anticancer agents can be divided into three groups. First group contains cancer-selective or semi-selective drugs that are effective in rare kinase- addictive cancers. For other malignancies, semi-selective drugs have to be judiciously combined with nonselective agents. The second group includes analogs of classic cytotoxic agents such as DNA alkylating agents, nucleoside analogs, and anti-microtubule agents. As expected, they have a marginal advantage over the existing cytotoxic drugs, nevertheless are more effective (in common cancers) than semi-selective agents. The third is a diverse group of tissue-selective agents that essentially attack the normal tissues of tumor origin and thus exploit the tissue-specific similarities between normal and cancer cells. Our analysis predicts that monotherapy with semi-selective agents will be limited to rare cancers. In most cancers, however, two anticancer strategies may be most fruitful: (a) combinations of cytotoxic drugs with semi-selective agents aimed at matching targets and (b) tissue-selective therapy aimed at normal and tumor cells of the same tissues.
机译：该评论讨论了过去十年由FDA批准的26种新的抗癌药物。根据其目标，这些抗癌剂可分为三组。第一组含有癌症选择性或半选择性药物，可在罕见的激酶上成瘾癌症中有效。对于其他恶性肿瘤，半选择性药物必须明显地与非选择性药剂结合。第二组包括经典细胞毒性剂的类似物，例如DNA烷基化剂，核苷类似物和抗微管剂。正如预期的那样，它们对现有的细胞毒性药物具有边际优势，然而，比半选择性药剂更有效（在常见的癌症中）。第三是多样的组织选择剂组，基本上攻击肿瘤起源的正常组织，从而利用正常和癌细胞之间的组织特异性相似性。我们的分析预测，半选择性药物的单药治疗将仅限于罕见的癌症。然而，在大多数癌症中，两种抗癌策略可能是最富有成熟的：（a）细胞毒性药物的组合与半选择性药物的组合，旨在匹配靶标和（b）组织选择性治疗的靶向靶向靶向的同一组织的正常和肿瘤细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号